<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Thu, 16 Jul 2026 16:08:57 -0400--><rss version="2.0">
    <channel>
        <title>Intensity Therapeutics, Inc. (INTS) SEC Filings</title>
        <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/rss</link>
        <description>Intensity Therapeutics, Inc. (INTS) - All SEC Filings</description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/intensitytherapeutics/files/theme/images/logo-sm.png</url>
                <title>Intensity Therapeutics, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[S-8 - Securities to be offered to employees in employee benefit plans]]></title>
                <description><![CDATA[4 Related Documents: S-8, EX-FILING FEES, EX-5.1, EX-23.1]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000054/0001567264-26-000054.pdf</link>
                <pubDate>Wed, 08 Jul 26 16:01:22 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000054/0001567264-26-000054.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[4 - Statement of changes in beneficial ownership of securities]]></title>
                <description><![CDATA[4]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001895944-26-000006/0001895944-26-000006.pdf</link>
                <pubDate>Wed, 01 Jul 26 16:10:03 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001895944-26-000006/0001895944-26-000006.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[4 - Statement of changes in beneficial ownership of securities]]></title>
                <description><![CDATA[4]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001524547-26-000007/0001524547-26-000007.pdf</link>
                <pubDate>Wed, 01 Jul 26 16:08:50 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001524547-26-000007/0001524547-26-000007.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[8-K - Current report]]></title>
                <description><![CDATA[8-K]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000049/0001567264-26-000049.pdf</link>
                <pubDate>Tue, 16 Jun 26 16:15:37 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000049/0001567264-26-000049.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[8-K - Current report]]></title>
                <description><![CDATA[2 Related Documents: 8-K, EX-99.1]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000047/0001567264-26-000047.pdf</link>
                <pubDate>Thu, 07 May 26 16:18:32 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000047/0001567264-26-000047.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report [Sections 13 or 15(d)]]]></title>
                <description><![CDATA[5 Related Documents: 10-Q, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000046/0001567264-26-000046.pdf</link>
                <pubDate>Thu, 07 May 26 16:02:29 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000046/0001567264-26-000046.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[ARS - Annual Report to Security Holders]]></title>
                <description><![CDATA[ARS]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000037/0001567264-26-000037.pdf</link>
                <pubDate>Thu, 30 Apr 26 16:13:12 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000037/0001567264-26-000037.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material]]></title>
                <description><![CDATA[DEFA14A]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000036/0001567264-26-000036.pdf</link>
                <pubDate>Thu, 30 Apr 26 16:13:02 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000036/0001567264-26-000036.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DEF 14A - Definitive proxy statements]]></title>
                <description><![CDATA[DEF 14A]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000035/0001567264-26-000035.pdf</link>
                <pubDate>Thu, 30 Apr 26 16:07:48 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000035/0001567264-26-000035.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[4 - Statement of changes in beneficial ownership of securities]]></title>
                <description><![CDATA[4]]></description>
                <link>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001238705-26-000005/0001238705-26-000005.pdf</link>
                <pubDate>Mon, 30 Mar 26 17:30:19 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001238705-26-000005/0001238705-26-000005.pdf</guid>
                                                                            </item>
            </channel>
</rss>